相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
Rajul K. Jain et al.
CLINICAL CANCER RESEARCH (2010)
Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
Thomas Puchalski et al.
CLINICAL CANCER RESEARCH (2010)
Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development
P. J. Lowe
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
Anthe S. Zandvliet et al.
INVESTIGATIONAL NEW DRUGS (2010)
Pharmacometrics 2020
Jogarao V. S. Gobburu
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Model-Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development
Jeffrey D. Wetherington et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics
Balaji M. Agoram
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
Y. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Laurent Claret et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
N. M. G. M. Appels et al.
BRITISH JOURNAL OF CANCER (2008)
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Jian-Feng Lu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients
Jing Li et al.
CLINICAL CANCER RESEARCH (2008)
PK/PD modelling and simulations: utility in drug development
Iris Rajman
DRUG DISCOVERY TODAY (2008)
Recommended changes to oncology clinical trial design: Revolution or evolution?
Mark J. Ratain et al.
EUROPEAN JOURNAL OF CANCER (2008)
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose selection in phase I studies: Why we should always go for the top
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung cancer
Theodore G. Karrison et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
R Bruno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval
J Goffin et al.
CLINICAL CANCER RESEARCH (2005)
Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies
EK Rowinsky
CLINICAL CANCER RESEARCH (2004)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
Maximizing the potential of bevacizumab in cancer treatment
E Bergsland et al.
ONCOLOGIST (2004)
Challenges of PK/PD measurements in modern drug development
P Workman
EUROPEAN JOURNAL OF CANCER (2002)
Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels
GJS Rustin et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
